← Leaderboards
P Jeffrey Conn
Vanderbilt University
$37,782,937
Attributed
$40,661,976
Total exposure
21
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.5M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$59,048,604 · 24
By mechanism
R01$29,605,976 · 9
U01$10,100,839 · 2
U19$9,491,113 · 4
R37$3,476,819 · 1
UG3$1,585,635 · 1
P30$1,440,717 · 1
Top collaborators
- Craig Lindsley10 shared
- Robert W Gereau5 shared
- Jerri Michelle Rook5 shared
- Colleen M Niswender4 shared
Most similar at Vanderbilt University
Same institution · by research overlap
- Craig Lindsley$38,671,033
- Jerri Michelle Rook$4,711,471
- Carrie Kimberly Jones$9,423,953
- Thilo Womelsdorf$6,643,968
- Zixiu Xiang$1,661,178
Others in their field
Top investigators on “Series”
- Lawrence Corey · Fred Hutchinson Cancer Center$445,660,381
- Kiran Datta · Leidos Biomedical Research, Inc.$292,634,066
- David R. Weir · University Of Michigan At Ann Arbor$276,156,779
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$231,733,045
- Dennis R. Burton · Scripps Research Institute$199,946,411
- Joel A Lipkin · Four Points Technology, Llc$183,862,844
Research focus
SeriesNovel StrategiesReceptorResponseSchizophreniaBehavioralAnimal ModelRodent ModelIn VivoAntipsychotic AgentsMediatingPropertyPharmaceutical PreparationsBrainBaseSymptomsTransmission ProcessAdverse EffectsMetabotropic Glutamate ReceptorsAgonistNeuronsSignal TransductionPhysiologicalCells
Grant awards (129)
Regulation of Signaling by mGluR5$601,066
R01 · FY2025 · MH · contact PI
Functions of Metabotropic Glutamate Receptor Subtypes$484,912
R01 · FY2025 · NS · contact PI
Regulation of Signaling by mGluR5$601,065
R01 · FY2024 · MH · contact PI
Functions of Metabotropic Glutamate Receptor Subtypes$470,363
R01 · FY2024 · NS · contact PI
Discovery of mGlu receptor PAMs for treatment of schizophrenia$678,065
R01 · FY2023 · MH · contact PI
Regulation of Signaling by mGluR5$601,065
R01 · FY2023 · MH · contact PI
Functions of Metabotropic Glutamate Receptor Subtypes$484,912
R01 · FY2023 · NS · contact PI
Novel mGlu5 Negative Allosteric Modulators as First-in-Class Non-Addictive Analgesic Therapeutics$191,208
UH3 · FY2023 · NS
Discovery of mGlu receptor PAMs for treatment of schizophrenia$707,149
R01 · FY2022 · MH · contact PI
Regulation of Signaling by mGluR5$601,065
R01 · FY2022 · MH · contact PI
Novel mGlu5 Negative Allosteric Modulators as First-in-Class Non-Addictive Analgesic Therapeutics$191,208
UH3 · FY2022 · NS
Functions of Metabotropic Glutamate Receptor Subtypes$165,235
R01 · FY2022 · NS · contact PI
Novel mGlu5 negative allosteric modulators as first-in-class non-addictive analgesic therapeutics$76,619
UH3 · FY2022 · NS
Discovery of mGlu receptor PAMs for treatment of schizophrenia$714,606
R01 · FY2021 · MH · contact PI
Functions of Metabotropic Glutamate Receptor Subtypes$484,535
R01 · FY2021 · NS · contact PI
Novel mGlu5 negative allosteric modulators as first-in-class non-addictive analgesic therapeutics$191,208
UH3 · FY2021 · NS
Discovery of mGlu receptor PAMs for treatment of schizophrenia$752,218
R01 · FY2020 · MH · contact PI
Functions of Metabotropic Glutamate Receptor Subtypes$522,143
R37 · FY2020 · NS · contact PI
Muscarinic Receptor Activators as Antipsychotic Agents$507,130
R01 · FY2020 · MH · contact PI
Regulation of Signaling by mGluR5$488,700
R01 · FY2020 · MH · contact PI
Novel mGlu5 negative allosteric modulators as first-in-class non-addictive analgesic therapeutics$1,585,635
UG3 · FY2019 · NS
Discovery of mGlu receptor PAMs for treatment of schizophrenia$752,218
R01 · FY2019 · MH · contact PI
Functions of Metabotropic Glutamate Receptor Subtypes$531,273
R37 · FY2019 · NS · contact PI
Muscarinic Receptor Activators as Antipsychotic Agents$507,130
R01 · FY2019 · MH · contact PI
Regulation of Signaling by mGluR5$488,700
R01 · FY2019 · MH · contact PI
Functions of Metabotropic Glutamate Receptor Subtypes$524,289
R37 · FY2018 · NS · contact PI
Muscarinic Receptor Activators as Antipsychotic Agents$507,130
R01 · FY2018 · MH · contact PI
Regulation of Signaling by mGluR5$488,700
R01 · FY2018 · MH · contact PI
Muscarinic Receptor Activators as Antipsychotic Agents$392,491
R01 · FY2018 · MH · contact PI
Development of an M1 PAM experimental therapeutic for schizophrenia$1,401,867
U19 · FY2017 · MH · contact PI
Muscarinic Receptor Activators as Antipsychotic Agents$507,130
R01 · FY2017 · MH · contact PI
Regulation of Signaling by mGluR5$488,700
R01 · FY2017 · MH · contact PI
Functions of Metabotropic Glutamate Receptor Subtypes$471,271
R37 · FY2017 · NS · contact PI
Administrative Core$76,834
U19 · FY2017 · MH · contact PI
Development of an M1 PAM experimental therapeutic for schizophrenia$1,827,730
U19 · FY2016 · MH · contact PI
Muscarinic Receptor Activators as Antipsychotic Agents$563,478
R01 · FY2016 · MH · contact PI
Regulation of Signaling by mGluR5$543,000
R01 · FY2016 · MH · contact PI
Functions of Metabotropic Glutamate Receptor Subtypes$471,271
R37 · FY2016 · NS · contact PI
Administrative Core$76,835
U19 · FY2016 · MH · contact PI
Development of an M1 PAM experimental therapeutic for schizophrenia$2,072,400
U19 · FY2015 · MH · contact PI
Development of mGIuR5 NAMS for Treatment of Major Depression$1,206,097
U19 · FY2015 · MH · contact PI
Functions of Metabotropic Glutamate Receptor Subtypes$471,271
R37 · FY2015 · NS · contact PI
Regulation of Signaling by mGluR5$437,426
R01 · FY2015 · MH · contact PI
Muscarinic receptor activators as antipsychotic agents$425,602
R01 · FY2015 · MH · contact PI
Postdoctoral Training in CNS Drug Discovery Research$226,675
T32 · FY2015 · MH · contact PI
Administrative Core$76,834
U19 · FY2015 · MH · contact PI
Administrative Core$66,312
U19 · FY2015 · MH · contact PI
Vanderbilt NCDDDG for Discovery of Novel Treatments for Schizophrenia$1,880,513
U01 · FY2014 · MH · contact PI
Development of mGIuR5 NAMS for Treatment of Major Depression$1,206,097
U19 · FY2014 · MH · contact PI
Functions of Metabotropic Glutamate Receptor Subtypes$485,301
R37 · FY2014 · NS · contact PI
Regulation of Signaling by mGluR5$437,426
R01 · FY2014 · MH · contact PI
Muscarinic receptor activators as antipsychotic agents$425,187
R01 · FY2014 · MH · contact PI
Discovery and Optimization of Selective Negative Allosteric Modulators of mGluR3$390,000
R01 · FY2014 · MH · contact PI
Postdoctoral Training in CNS Drug Discovery Research$222,031
T32 · FY2014 · MH · contact PI
Highly Selective Muscarinic Agents as Antiparkinsonian Therapy$219,129
P50 · FY2014 · NS · contact PI
Administrative Core$153,664
U01 · FY2014 · MH · contact PI
Administrative Core$66,313
U19 · FY2014 · MH · contact PI
Vanderbilt NCDDDG for Discovery of Novel Treatments for Schizophrenia$1,805,294
U01 · FY2013 · MH · contact PI
Development of mGIuR5 NAMS for Treatment of Major Depression$1,340,109
U19 · FY2013 · MH · contact PI
Regulation of Signaling by mGluR5$419,929
R01 · FY2013 · MH · contact PI
Muscarinic receptor activators as antipsychotic agents$407,793
R01 · FY2013 · MH · contact PI
Functions of Metabotropic Glutamate Receptor Subtypes$322,720
R01 · FY2013 · NS · contact PI
Highly Selective Muscarinic Agents as Antiparkinsonian Therapy$291,405
P50 · FY2013 · NS · contact PI
Postdoctoral Training in CNS Drug Discovery Research$234,886
T32 · FY2013 · MH · contact PI
Administrative Core$147,713
U01 · FY2013 · MH · contact PI
Administrative Core$73,685
U19 · FY2013 · MH · contact PI
Vanderbilt NCDDDG for Discovery of Novel Treatments for Schizophrenia$1,880,515
U01 · FY2012 · MH · contact PI
Regulation of Signaling by mGluR5$437,426
R01 · FY2012 · MH · contact PI
Muscarinic receptor activators as antipsychotic agents$424,393
R01 · FY2012 · MH · contact PI
Functions of Metabotropic Glutamate Receptor Subtypes$334,425
R01 · FY2012 · NS · contact PI
Postdoctoral Training in CNS Drug Discovery Research$235,979
T32 · FY2012 · MH · contact PI
Highly Selective Muscarinic Agents as Antiparkinsonian Therapy$234,554
P50 · FY2012 · NS · contact PI
Administrative Core$154,076
U01 · FY2012 · MH · contact PI
Vanderbilt NCDDDG for Discovery of Novel Treatments for Schizophrenia$1,874,484
U01 · FY2011 · MH · contact PI
Regulation of Signaling by mGluR5$435,064
R01 · FY2011 · MH · contact PI
Muscarinic receptor activators as antipsychotic agents$422,423
R01 · FY2011 · MH · contact PI
Functions of Metabotropic Glutamate Receptor Subtypes$334,425
R01 · FY2011 · NS · contact PI
Highly Selective Muscarinic Agents as Antiparkinsonian Therapy$240,698
P50 · FY2011 · NS · contact PI
Administrative Core$153,798
U01 · FY2011 · MH · contact PI
Postdoctoral Training in CNS Drug Discovery Research$117,782
T32 · FY2011 · MH · contact PI
Vanderbilt NCDDDG for Discovery of Novel Treatments for Schizophrenia$1,891,522
U01 · FY2010 · MH · contact PI
Recruitment of in Vivo Neuropharmacologist to Support CNS Drug Discovery Research$737,217
P30 · FY2010 · MH · contact PI
Functions of Metabotropic Glutamate Receptor Subtypes$339,063
R01 · FY2010 · NS · contact PI
Muscarinic receptor activators as novel antipsychotic agents$316,729
R01 · FY2010 · MH · contact PI
Regulation of Signaling by mGluR5$316,729
R01 · FY2010 · MH · contact PI
Highly Selective Muscarinic Agents as Antiparkinsonian Therapy$259,653
P50 · FY2010 · NS · contact PI
Functional effects of mGluR potentiators in the CNS$253,382
R01 · FY2010 · MH · contact PI
Administrative Core$159,260
U01 · FY2010 · MH · contact PI
Recruitment of in Vivo Neuropharmacologist to Support CNS Drug Discovery Research$703,500
P30 · FY2009 · MH · contact PI
Muscarinic receptor activators as novel antipsychotic agents$316,729
R01 · FY2009 · MH · contact PI
Regulation of Signaling by mGluR5$316,729
R01 · FY2009 · MH · contact PI
Functional effects of mGluR potentiators in the CNS$253,382
R01 · FY2009 · MH · contact PI
Muscarinic receptor activators as novel antipsychotic agents$77,500
R01 · FY2009 · MH · contact PI
Regulation of Signaling by mGluR5$77,500
R01 · FY2009 · MH · contact PI
Functional effects of mGluR potentiators in the CNS$77,500
R01 · FY2009 · MH · contact PI
Functions of Metabotropic Glutamate Receptor Subtypes$336,575
R01 · FY2008 · NS · contact PI
Regulation of Signaling by mGluR5$316,729
R01 · FY2008 · MH · contact PI
Muscarinic receptor activators as novel antipsychotic agents$316,729
R01 · FY2008 · MH · contact PI
Metabotropic Glutamate Receptors in Basal Ganglia$306,044
R01 · FY2008 · NS · contact PI
Functional effects of mGluR potentiators in the CNS$253,382
R01 · FY2008 · MH · contact PI
Metabotropic Glutamate Receptors in Basal Ganglia$76,750
R01 · FY2008 · NS · contact PI
Functions of Metabotropic Glutamate Receptor Subtypes$336,209
R01 · FY2007 · NS · contact PI
Regulation of Signaling by mGluR5$316,299
R01 · FY2007 · MH · contact PI
Muscarinic receptor activators as novel antipsychotic agents$316,213
R01 · FY2007 · MH · contact PI
Metabotropic Glutamate Receptors in Basal Ganglia$306,938
R01 · FY2007 · NS · contact PI
Functional effects of mGluR potentiators in the CNS$253,314
R01 · FY2007 · MH · contact PI
mGluR4 Potentiators as a Treatment for Parkinson's Disease$167,407
R21 · FY2007 · NS · contact PI
Functions of Metabotropic Glutamate Receptor Subtypes$344,745
R01 · FY2006 · NS · contact PI
Regulation of Signaling by mGluR5$324,240
R01 · FY2006 · MH · contact PI
Muscarinic receptor activators as antipsychotic agents$324,063
R01 · FY2006 · MH · contact PI
Metabotropic Glutamate Receptors in Basal Ganglia$316,567
R01 · FY2006 · NS · contact PI
Functional effects of mGluR potentiators in the CNS$259,958
R01 · FY2006 · MH · contact PI
mGluR4 Potentiators as a Treatment for Parkinson's Disease$171,563
R21 · FY2006 · NS · contact PI
Functions of Metabotropic Glutamate Receptor Subtypes$350,729
R01 · FY2005 · NS
Metabotropic Glutamate Receptors in Basal Ganglia$331,746
R01 · FY2005 · NS
REGULATION OF SIGNALING BY MGLUR5$302,000
R01 · FY2005 · MH
REGULATION OF SIGNALING BY MGLUR5$302,000
R01 · FY2004 · MH
Throughput Assay:Allosteric Potentiator of GluR (RMI)$75,500
R03 · FY2004 · NS
FUNCTIONS OF METABOTROPIC GLUTAMATE RECEPTOR SUBTYPES$339,750
R01 · FY2003 · NS
REGULATION OF SIGNALING BY MGLUR5$272,624
R01 · FY2003 · MH
METABOTROPIC GLUTAMATE RECEPTORS IN THE BASAL GANGLIA$0
P50 · FY2002 · NS
REGULATION OF SIGNALING BY MGLUR5$343,313
R01 · FY2001 · MH
FUNCTIONS OF METABOTROPIC GLUTAMATE RECEPTOR SUBTYPES$342,188
R01 · FY2001 · NS
METABOTROPIC GLUTAMATE RECEPTORS IN THE BASAL GANGLIA$0
P50 · FY2001 · NS
FUNCTIONS OF METABOTROPIC GLUTAMATE RECEPTOR SUBTYPES$344,344
R01 · FY2000 · NS
CONTROL OF NMDA RECEPTORS BY HIPPOCAMPUS MUSCARINIC REC$215,532
R01 · FY2000 · NS
NEUROMODULATORY ROLES OF MUSCARINIC RECEPTOR SUBTYPES$176,750
R01 · FY2000 · NS
METABOTROPIC GLUTAMATE RECEPTORS IN THE BASAL GANGLIA$0
P50 · FY2000 · NS
METABOTROPIC GLUTAMATE RECEPTORS IN THE BASAL GANGLIA$0
P50 · FY2000 · NS